ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

SHP Shire

4,690.00
0.00 (0.00%)
18 Apr 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Shire LSE:SHP London Ordinary Share JE00B2QKY057 ORD 5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 4,690.00 0.00 01:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

Shire plc Shire Plc : Directorate Change

08/12/2017 4:30pm

Dow Jones News


Shire (LSE:SHP)
Historical Stock Chart


From Apr 2019 to Apr 2024

Click Here for more Shire Charts.
TIDMSHP 
 
 
   Chief Financial Officer update 
 
   December 8, 2017 - Shire plc (LSE: SHP, NASDAQ: SHPG), the global 
biotech leader in rare diseases, announced on August 21, 2017, that Jeff 
Poulton, Chief Financial Officer, would leave Shire at the end of the 
year.  On November 20, 2017, Shire announced that Thomas Dittrich will 
join the company as Chief Financial Officer in early 2018. 
 
   Shire today announces that Jeff Poulton will leave on December 31, 2017, 
and John Miller, Shire's Senior Vice President of Finance, will be 
appointed Interim Chief Financial Officer with effect from January 1, 
2018, until Mr. Dittrich commences his employment with Shire. 
 
   Mr. Miller joined Shire in 2004 and, in addition to his current role in 
which he has served since March 2015, has served in a number of 
positions including, in the past five years, as Vice President of 
Finance, Neuroscience from June 2010 to March 2015. 
 
   For further information please contact: 
 
 
 
 
Investor Relations 
Ian Karp             ikarp@shire.com         +1 781 482 9018 
Robert Coates        rcoates@shire.com      +44 203 549 0874 
 
  Media 
Lisa Adler           lisa.adler@shire.com    +1 617 588 8607 
Katie Joyce          kjoyce@shire.com        +1 781 482 2779 
 
 
   NOTES TO EDITORS 
 
   About Shire 
 
   Shire is the global leader in serving patients with rare diseases. We 
strive to develop best-in-class therapies across a core of rare disease 
areas including hematology, immunology, genetic diseases, neuroscience, 
and internal medicine with growing therapeutic areas in ophthalmics and 
oncology. Our diversified capabilities enable us to reach patients in 
more than 100 countries who are struggling to live their lives to the 
fullest. 
 
   We feel a strong sense of urgency to address unmet medical needs and 
work tirelessly to improve people's lives with medicines that have a 
meaningful impact on patients and all who support them on their journey. 
 
   www.shire.com 
 
   This announcement is distributed by Nasdaq Corporate Solutions on behalf 
of Nasdaq Corporate Solutions clients. 
 
   The issuer of this announcement warrants that they are solely 
responsible for the content, accuracy and originality of the information 
contained therein. 
 
   Source: Shire plc via Globenewswire 
 
 
 
 

(END) Dow Jones Newswires

December 08, 2017 11:15 ET (16:15 GMT)

Copyright (c) 2017 Dow Jones & Company, Inc.

1 Year Shire Chart

1 Year Shire Chart

1 Month Shire Chart

1 Month Shire Chart

Your Recent History

Delayed Upgrade Clock